Cell Therapy News
Cell Therapy News is an online resource dedicated to sharing the latest cell therapy, gene therapy, and regenerative medicine research.
Bristol Myers Angles Breyanzi for Another Blood Cancer As It Works to Close Gilead’s CAR-T Lead
With another trial win, Bristol Myers Squibb is touting Breyanzi as the CD19-directed CAR-T therapy with positive readouts in most cancer types. The latest...
Phase I Clinical Trial of B-Cell Maturation Antigen (BCMA) NEX-T® Chimeric Antigen Receptor (CAR) T Cell Therapy CC-98633/BMS-986354 in Participants with Triple-Class Exposed Multiple...
[Leukemia] Researchers conducted a Phase I clinical trial of BMS-986354, an autologous BCMA CAR T manufactured using an optimized NEX-T® process, in participants with triple-class exposed, refractory multiple myeloma.
Mesenchymal Stromal Cell Therapy: Progress to Date and Future Outlook
[Molecular Therapy] Scientists provide background on the history and potential therapeutic value of mesenchymal stromal/stem cells (MSC), an overview of MSC products with regulatory approval, and a summary of registered MSC trials.
A Neoantigen Vaccine Generates Antitumor Immunity in Renal Cell Carcinoma
[Nature] Investigators conducted a Phase I trial to test a neoantigen-targeting personalized cancer vaccine (PCV) in patients with high-risk, fully resected clear cell renal cell carcinomawith or without ipilimumab administered adjacent to the vaccine.
FLASH Radiation Reprograms Lipid Metabolism and Macrophage Immunity and Sensitizes Medulloblastoma to CAR T Cell Therapy
[Nature Cancer] Using a genetically engineered mouse model of medulloblastoma, researchers showed that FLASH radiation stimulated proinflammatory polarization in tumor macrophages.
Targeting the TRIM21-PD-1 Axis Potentiates Immune Checkpoint Blockade and CAR T Cell Therapy
[Molecular Therapy] Researchers reported that TRIM21 impaired CD8+ T cell activation and anti-tumor immunity. Mechanistically, TRIM21 catalyzed the K63-linked ubiquitination on PD-1 at K233, leading to stabilization of PD-1 through antagonizing its K48-linked ubiquitination and degradation.
Nature-Inspired Platform Nanotechnology for RNA Delivery to Myeloid Cells and Their Bone Marrow Progenitors
[Nature Nanotechnology] Researchers presented a nanotechnology platform based on natural lipoproteins, designed for delivering small interfering RNA, antisense oligonucleotides, and messenger RNA to myeloid cells and hematopoietic stem and progenitor cells in the bone marrow.
Novel Strategies to Manage CAR-T Cell Toxicity
[Nature Reviews Drug Discovery] Investigators summarize the current management of cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome, and review T cell- and myeloid cell-intrinsic druggable targets and cellular engineering strategies to develop safer CAR-T cells.
A Universal and Wide-Range Cytosine Base Editor via Domain-Inlaid and Fidelity-Optimized CRISPR-FrCas9
[Nature Communications] A series of iteratively improved cytosine base editors were constructed using the FrCas9 nickase with the unique protospacer adjacent motif palindromic structure to alleviate these challenges.
Vaccine-Induced T Cell Receptor T Cell Therapy Targeting a Glioblastoma Stemness Antigen
[Nature Communications] Researchers identified a therapeutic HLA-A*02-restricted protein tyrosine phosphatase receptor type Z1-reactive T cell receptor retrieved from a vaccinated glioblastoma patient.
Selective JAK2 Pathway Inhibition Enhances Anti-Leukemic Functionality in CD19 CAR-T Cells
[Cancer Immunology Immunotherapy] The authors explored the combinatorial use of a selective type II JAK2 inhibitor, CHZ868, with CD19 CAR-T cells, revealing a synergistic enhancement of anti-leukemic activity across B-cell tumor models irrespective of JAK2 mutational status.
Harnessing the Power of TCR-T Cell Therapy: A New Era in Cancer Immunotherapy
[Cancer Letters] The authors discuss the FDA's approval of "afami-cel," a first-in-class gene-modified autologous T cell therapy, for the treatment of specific solid tumor indications.
Published since 2002, Cell Therapy News is our longest running online publication. Our editorial team curates the top publications, reviews, and news on in vivo gene therapy, cell therapy, and immunotherapy research. With over 15,000 subscribers and followers across our website, email newsletter, and Twitter feed, we are proud to facilitate the communication of cutting-edge cell therapy innovations.